李庆双　秦逸辉　李毅

【摘要】 目的：探究瑞舒伐他汀、纳洛酮和依达拉奉注射液三药联合治疗急性脑出血的效果及不良反应。方法：选取笔者所在医院2017年

1月-2019年9月收治的105例急性脑出血患者为研究对象，随机分为A组、B组、C组，每组35例。A组给予依达拉奉注射液治疗，B组给予瑞舒伐他汀+依达拉奉注射液治疗，C组给予瑞舒伐他汀+依达拉奉注射液+纳洛酮联合治疗，治疗时间为14 d;比较三组临床总有效率及治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数评定量表评分、药物不良反应情况。结果：C组临床总有效率（91.43%）高于A组（57.14%）和B组（80.00%），差異有统计学意义（P<0.05）。治疗后三组NIHSS评分均低于治疗前，且C组NIHSS评分低于A组、B组，差异均有统计学意义（P<0.05）。治疗后三组Barthel指数均高于治疗前，且C组Barthel指数高于A组、B组，差异均有统计学意义（P<0.05）。三组均未见明显不良反应。结论：急性脑出血接受瑞舒伐他汀、纳洛酮和依达拉奉注射液三药联合治疗，可有效改善神经功能，用药安全性较高，值得临床推广。

【关键词】 瑞舒伐他汀 依达拉奉注射液 纳洛酮 急性脑出血 临床效果

doi：10.14033/j.cnki.cfmr.2020.18.020 文献标识码 B 文章编号 1674-6805（2020）18-00-03

Comparison of the Therapeutic Effects of Rosuvastatin， Naloxone and Edaravone Injection in Treatment of Acute Cerebral Hemorrhage/LI Qingshuang， QIN Yihui， LI Yi. //Chinese and Foreign Medical Research， 2020， 18（18）： -49

[Abstract] Objective： To investigate the efficacy and side effects of Rosuvastatin， Naloxone and Edaravone Injection in treatment of acute cerebral hemorrhage. Method： A total of 105 patients with acute cerebral hemorrhage admitted to the authors hospital from January 2017 to September 2019 were selected， and were randomly divided into three groups： group A， group B and group C， 35 cases in each group. Group A was treated withEdaravone injection， group B was treated with Rosuvastatin+Edaravone injection， and group C was treated with Rosuvastatin+Edaravone Injection +Naloxone for 14 days. The total clinical efficacy， NIHSS score， Barthel index score before and after treatment and adverse drug reactions were compared. Result： The total effective rate in group C （91.43%） was higher than that in group A （57.14%） and group B （80.00%）， the difference was statistically significant （P<0.05）. After treatment， the NIHSS scores in the three groups were lower than those before treatment， and the NIHSS score in group C was lower than those in group A and group B， the differences were statistically significant （P<0.05）. The Barthel index in the three groups were higher than those before treatment， and the Barthel index in group C was higher than those in group A and group B， the differences were statistically significant （P<0.05）. No significant adverse reactions were observed in the three groups. Conclusion： The combination of Rosuvastatin， Naloxone and Edaravone Injection can effectively improve the neurological function of patients with acute cerebral hemorrhage， and the drug safety is high， which is worthy of clinical promotion.

[Key words] Rosuvastatin Edaravone Injection Naloxone Acute cerebral hemorrhage Clinical effect

First-authors address： The 73th Military Hospital of the Army， Xiamen 361000， China

急性脑出血是发病率较高的一种脑血管疾病，具有起病急、病死率高等特点[1]。神经功能在脑出血后会严重恶化，很大程度上和血肿周围组织继发脑损伤和脑水肿有关[2]。其中，纳洛酮属于非特异性阿片受体阻断剂，用藥之后可以快速经过血脑屏障与阿片受体相结合，使患者脑组织细胞增强对氧、葡萄糖的摄入，从而改善脑组织缺氧状态[3]。而依达拉奉是一种抗氧化剂和自由基清除剂，属于神经保护药物，已证实依达拉奉可促进神经功能的恢复[4]。瑞舒伐他汀是一种强效调脂药物，其对神经递质脑细胞损伤具有改善作用，有助于促进血管神经再生[5]。本研究主要探讨瑞舒伐他汀、纳洛酮和依达拉奉注射液三药联合治疗急性脑出血的效果，具体如下。……